Research ExplorerPublicationsNebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der ...

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen

Standard

Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen. / Lieb, V; Rink, M; Sikic, D; Keck, B.

In: UROLOGE, Vol. 55, No. 6, 06.2016, p. 805-12.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lieb, V, Rink, M, Sikic, D & Keck, B 2016, 'Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen', UROLOGE, vol. 55, no. 6, pp. 805-12. https://doi.org/10.1007/s00120-016-0090-9

APA

Lieb, V., Rink, M., Sikic, D., & Keck, B. (2016). Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen. UROLOGE, 55(6), 805-12. https://doi.org/10.1007/s00120-016-0090-9

Vancouver

Lieb V, Rink M, Sikic D, Keck B. Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen. UROLOGE. 2016 Jun;55(6):805-12. https://doi.org/10.1007/s00120-016-0090-9

Bibtex

@article{ab04ec33ff0c4243850f8f5c4b576a54,
title = "Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen",
abstract = "For approximately one decade, tyrosinkinase inhibitors (TKIs, smart drugs) have dramatically changed and improved the treatment of patients suffering from metastasized renal cell carcinoma. However, the different drugs have substantial side effects. Especially gastrointestinal symptoms may be problematic for patients. These side effects represent a challenge for the physician. On the one hand, dosage modifications and treatment interruption should be avoided to minimize the risk for progression. On the other hand, only mild side effects are tolerable for the patient. Based on a literature review, a clear overview of the incidence of possible side effects for the drugs axitinib, cabozantinib, pazopanib, sorafenib, and sunitinib is provided. Furthermore, we give a practical guide on how to prevent and treat the different gastrointestinal side effects. Finally, it is pointed out when dosage modifications or interruption of treatment are necessary and how to expeditiously re-escalate the treatment after mitigation of side effects.",
keywords = "English Abstract, Journal Article",
author = "V Lieb and M Rink and D Sikic and B Keck",
year = "2016",
month = jun,
doi = "10.1007/s00120-016-0090-9",
language = "Deutsch",
volume = "55",
pages = "805--12",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie:Gastrointestinale Nebenwirkungen

AU - Lieb, V

AU - Rink, M

AU - Sikic, D

AU - Keck, B

PY - 2016/6

Y1 - 2016/6

N2 - For approximately one decade, tyrosinkinase inhibitors (TKIs, smart drugs) have dramatically changed and improved the treatment of patients suffering from metastasized renal cell carcinoma. However, the different drugs have substantial side effects. Especially gastrointestinal symptoms may be problematic for patients. These side effects represent a challenge for the physician. On the one hand, dosage modifications and treatment interruption should be avoided to minimize the risk for progression. On the other hand, only mild side effects are tolerable for the patient. Based on a literature review, a clear overview of the incidence of possible side effects for the drugs axitinib, cabozantinib, pazopanib, sorafenib, and sunitinib is provided. Furthermore, we give a practical guide on how to prevent and treat the different gastrointestinal side effects. Finally, it is pointed out when dosage modifications or interruption of treatment are necessary and how to expeditiously re-escalate the treatment after mitigation of side effects.

AB - For approximately one decade, tyrosinkinase inhibitors (TKIs, smart drugs) have dramatically changed and improved the treatment of patients suffering from metastasized renal cell carcinoma. However, the different drugs have substantial side effects. Especially gastrointestinal symptoms may be problematic for patients. These side effects represent a challenge for the physician. On the one hand, dosage modifications and treatment interruption should be avoided to minimize the risk for progression. On the other hand, only mild side effects are tolerable for the patient. Based on a literature review, a clear overview of the incidence of possible side effects for the drugs axitinib, cabozantinib, pazopanib, sorafenib, and sunitinib is provided. Furthermore, we give a practical guide on how to prevent and treat the different gastrointestinal side effects. Finally, it is pointed out when dosage modifications or interruption of treatment are necessary and how to expeditiously re-escalate the treatment after mitigation of side effects.

KW - English Abstract

KW - Journal Article

U2 - 10.1007/s00120-016-0090-9

DO - 10.1007/s00120-016-0090-9

M3 - SCORING: Zeitschriftenaufsatz

C2 - 27146873

VL - 55

SP - 805

EP - 812

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 6

ER -